To Evaluate IOL Position, Clinical Outcome of PanOptix in High Myopic Cataract Patients

Launched by WENZHOU MEDICAL UNIVERSITY · Sep 4, 2021

Keywords

ClinConnect Summary

A prospective, single center study to evaluate IOL position, clinical outcome of PanOptix in high myopic cataract patients.

The objective of this study to investigate the refractive and visual performance of PanOptix and explore their correlation with ELP change, capsular bending formation, IOL tilt/decentration in high myopic cataract patients.

PanOptix IOL provides good refractive outcomes and visual quality because of few ELP change, fast capsular bending formation and few tilt and decentration in high myopic cataract patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients over 18 years old
• • 26 ≤Axial length\<30mm, IOL power ≥6D (PanOptix IOL power is available +6D-+30D )
• • Eyes with corneal astigmatism less than 1.0D (IOLMaster 700, Carl Zeiss Meditec AG)
• • Eyes with pupil diameter between 3 and 5.5 mm (iTrace, Tracey Technology, Houston, Texas, USA)
• • Eyes with angle kappa and angle Alpha ≤0.50 mm (iTrace);
• • Eyes with corneal spherical aberration ≤ 0.50 (Pentacam).
• Exclusion Criteria:
• • Irregular corneal astigmatism
• • Serious intraoperative complications, glaucoma, pseudoexfoliation syndrome, uveitis, macular degeneration or other retinal impairment
• • Moderate-severe dry eye, corneal scarring, amblyopia
• • Patients who can't cooperate with post-op 3 months follow-up.

Trial Officials